
A device that uses flickering light and rhythmic clicking sounds to stimulate the brain failed to slow memory loss in people with Alzheimer‘s disease, according to results from a highly anticipated clinical trial.
The device, called Spectris AD, consists of goggles paired with headphones that patients wear for an hour a day at home. The flickering light-and-sound show is designed to induce brain activity called gamma waves, which have been linked to attention and memory.
But after a year of treatment, participants who used the device did not show any improvement in their cognitive function compared to those assigned to a sham treatment, reported Cognito Therapeutics in Cambridge, Massachusetts, at the Clinical Trials on Alzheimer's Disease meeting held in Boston, Massachusetts, on 16 November.
While disappointed by the results, Christian Howell, Cognito’s chief executive, said the results show beneficial signs for patients with mild cognitive impairment and the company plans to file for approval from the US Food and Drug Administration (FDA) next year.
“The effect that we saw in the mild subgroup was so meaningful,” he said. “It just gives us optimism as we move forward.”
But researchers are not convinced. “The trial was negative,” says Eric McDade, a neurologist at Washington University School of Medicine in St. Louis, who was not involved in the study. “If anything is going to happen after this, it should be a follow-up study in that mild population,” he says.
Flashing signs
In the trial, 673 people with Alzheimer’s disease were randomly assigned to use either an active or a sham Spectris AD device for 60 minutes a day for 12 months. Those who used the active device scored, on average, 8.97 points worse after the year on a 156-point scale that measured cognition and ability to perform daily activities. Participants who used the sham device declined by 8.82 points.

Can flashing lights stall Alzheimer’s? What the science shows
Howell says that the device was more effective in patients with mild, rather than moderate, cognitive impairment. In the mild-impairment group, active-device users experienced 41.6% slower decline than sham-device users — a difference of 3 points on average.
For Rob Howard, a psychiatrist at University College London who specializes in dementia, this data is exploratory rather than a persuasive proof of efficacy.
“If this was a drug, such a clear failure would mean that a company would not proceed to seek regulatory approval,” says Howard. The safety of the device doesn’t make it any more useful to patients, he adds.
Previous trials of Spectris AD haven’t panned out either, adds Howard. In 2024, a smaller trial of the device failed to slow the decline of cognitive and functional abilities in people with Alzheimer’s disease1.
Divisive devices
The results are a setback for researchers who have been working to understand how gamma brainwave modulation could bolster brain health.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research